JCM
Home Help [Feedback] [For Subscribers] [Archive] [Search] --
JCM Accepts, published online ahead of print on 7 November 2007
This Article
Right arrow Full Text (PDF)
Right arrow Other Versions of this Article:
JCM.01623-07v1
46/1/192    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Martró, E.
Right arrow Articles by Ausina, V.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Martró, E.
Right arrow Articles by Ausina, V.
J. Clin. Microbiol. doi:10.1128/JCM.01623-07
Copyright (c) 2007, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights Reserved.

Evaluation of a new assay for hepatitis C virus (HCV) genotyping targeting both 5'NC and NS5b genomic regions, in comparison with reverse hybridization and sequencing methods

Elisa Martró, Victoria González, Andrew J. Buckton, Verónica Saludes, Gema Fernández, Lurdes Matas, Ramón Planas, and Vicenç Ausina*

Microbiology Department, Hospital Universitari Germans Trias i Pujol, Universitat Autònoma de Barcelona, Badalona, Spain; Centro de Investigación Biomédica en red de Epidemiología y Salud Pública (CIBERESP), Spain; Virus Reference Department, Health Protection Agency, London, United Kingdom; Liver Unit, Hospital Universitari Germans Trias i Pujol, Badalona, Spain; Centro de Investigación Biomédica en red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Spain

* To whom correspondence should be addressed. Email: vausina{at}ns.hugtip.scs.es.


   Abstract

We report the evaluation of a new real-time PCR assay for hepatitis C virus (HCV) genotyping. The assay design is such that genotype 1 isolates are typed by amplification targeting the NS5b subgenomic region. Non-genotype 1 isolates are typed by type-specific amplicon detection in the 5'non-coding region (5'NC) (method 1: HCV Genotyping ASR assay). This method was compared with 5'NC reverse hybridization (method 2: InnoLiPA HCV II) and 5'NC sequencing (method 3: Trugene HCV 5'NC). Two hundred-ninety five sera were tested by method 1; 223 of them were also typed by method 2 and 89 by method 3. Sequencing and phylogenetic analysis of an NS5b fragment was used to resolve discrepant results. Suspected multiple genotype infections were confirmed by PCR-cloning and Pyrosequencing. Even though a 2% rate of indeterminates was obtained with method 1, concordance at the genotype level with methods 2 and 3 was high. Among eight discordant results, five mixed infections were confirmed. Genotype 1 subtyping efficiencies were 100%, 77%, and 74% for methods 1, 2, and 3, respectively; there were 11/101 discordants between methods 1 and 2 (method 1 was predominantly correct), and 2/34 between methods 2 and 3. Regarding genotype 2, subtyping efficiencies were 100%, 45% and 92% by methods 1, 2 and 3, respectively; NS5b sequencing of discordants (16/17) revealed a putative new subtype within genotype 2, and that most subtype calls were not correct. Although only sequencing-based methods provide the possibility of identifying new variants, the real-time PCR method is rapid, straightforward, and simple to interpret, thus providing a good single-step alternative to more time-consuming assays.







Home Help [Feedback] [For Subscribers] [Archive] [Search] --
Antimicrob. Agents Chemother. Clin. Microbiol. Rev.
Clin. Vaccine Immunol. ALL ASM JOURNALS

Copyright © 2007 by the American Society for Microbiology. All rights reserved.